Oliceridine

An intravenous opioid used in hospitals and monitored settings for acute pain severe enough to need an IV opioid.

psilodex.org/m/oliceridine · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: 1.3–3 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Oliceridine”, v2026.10.05. psilodex.org/m/oliceridine

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Hospital use (IV)

FDA-approved for

Acute pain severe enough to require an intravenous opioid when other treatments are inadequate (adults)

Sources [1]

Other safety

Boxed warning: addiction, abuse and misuse; life-threatening respiratory depression; and profound sedation, respiratory depression, coma and death when combined with benzodiazepines or other CNS depressants, including alcohol.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; this hospital opioid sedates and slows breathing, which psilocybin does not. Stopping it suddenly after regular use can cause withdrawal.

Detail Oliceridine is an intravenous full mu-opioid agonist (a strong opioid) used in hospital for acute pain. It causes sedation and respiratory depression (slowed breathing), which add to other CNS depressants (sedating drugs). Psilocybin does not depress breathing. Its label reports serotonin syndrome when opioids are combined with serotonergic (serotonin-boosting) drugs; there are no psilocybin data. Also, the label reports severe hypotension (low blood pressure). It also reports mild QT prolongation (a heart-rhythm change) at daily doses above 27 mg, and more frequent seizures in seizure disorders. Stopping it suddenly after regular use can cause withdrawal. Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: 1.3–3 h (FDA label, checked 2026-10-04) Inactive metabolites about 44 h.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

7 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]
Opioid: Activates opioid receptors, causing pain relief, sedation and slowed breathing at higher doses. Psilocybin does not slow breathing, but stopping an opioid suddenly can cause withdrawal. Sources [1]
QT-prolonging: Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

OLINVYK (oliceridine) injection (Trevena) · FDA label (DailyMed) — Opioid: 12.1 "Oliceridine is a full opioid agonist and is relatively selective for the mu-opioid receptor." | Sedating or CNS depressant: Boxed Warning "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death." | Serotonergic: 7 Drug Interactions "The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome." | QT-prolonging: 5.5 Potential for QT prolongation with Daily Doses exceeding 27 mg "In both studies, there was mild QTc interval prolongation." | Lowers blood pressure or causes orthostasis: 5.10 "OLINVYK may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients." | Lowers seizure threshold or carries seizure risk: 5.13 "may increase the frequency of seizures in patients with seizure disorders" | Withdrawal or rebound if stopped abruptly: 5.14 "Do not rapidly reduce or abruptly discontinue OLINVYK in a patient physically dependent on opioids." | 12.3 "The half-life of these metabolites (~44 hours) is much longer than that of unchanged oliceridine (1.3-3 hours)."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →